Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib : A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Identifieur interne : 009C87 ( Main/Exploration ); précédent : 009C86; suivant : 009C88Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib : A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
Auteurs : Martine Van Glabbeke [Belgique] ; Jaap Verweij [Pays-Bas] ; Paolo G. Casali [Italie] ; John Simes [Australie] ; Axel Le Cesne [France] ; Peter Reichardt [Allemagne] ; Rolf Issels [Allemagne] ; Ian R. Judson [Royaume-Uni] ; Allan T. Van Oosterom [Belgique] ; Jean-Yves Blay [France]Source :
- European journal of cancer : (1990) [ 0959-8049 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- geographic : Italie.
- topic : Homme, Recherche, Pharmacologie, Cancer.
English descriptors
- KwdEn :
- Advanced stage, Antineoplastic agent, Australasia, Cancer, Cancerology, Clinical trial, Enzyme inhibitor, Europe, European Organization for Research and Treatment of Cancer, Gastrointestinal stromal tumor, Gut, Human, Imatinib, Italy, Malignant tumor, Pharmacology, Prognosis, Protein-tyrosine kinase, Research, Sarcoma, Toxicity, Treatment.
Abstract
The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to receive imatinib at different doses. The correlation between toxicities occurring with a Common Toxicity Criteria (CTC) grade 2 or more (non-haematological) or grade 3 or 4 (haematological) and imatinib dose, age, sex, performance status, original disease site, site and size of lesions at trial entry, baseline haematological and biological parameters was investigated. Anaemia was correlated with dose and baseline haemoglobin level, and neutropaenia with baseline neutrophil count and haemoglobin level. The risk of non-haematological toxicities was dose dependent and higher in females (oedema, nausea, diarrhoea), and in patients of advanced age (oedema, rash fatigue), poor performance status (fatigue and nausea), prior chemotherapy (fatigue), tumour of identified gastrointestinal origin (diarrhoea) and small lesions (rash). A multivariate risk calculator that can be used in the clinic for individual patients is proposed.
Affiliations:
- Allemagne, Australie, Belgique, France, Italie, Pays-Bas, Royaume-Uni
- Angleterre, Auvergne-Rhône-Alpes, Bavière, Berlin, District de Haute-Bavière, Grand Londres, Hollande-Méridionale, Rhône-Alpes, Région de Bruxelles-Capitale
- Berlin, Bruxelles, Londres, Lyon, Munich, Rotterdam
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 004164
- to stream PascalFrancis, to step Curation: 001F31
- to stream PascalFrancis, to step Checkpoint: 003D58
- to stream Main, to step Merge: 00A780
- to stream Main, to step Curation: 009C87
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib : A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)</title><author><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>EORTC Data Center, Av. E. Mounier, 83, Bte 8</s1><s2>1200, Brussels</s2><s3>BEL</s3><sZ>1 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Erasmus University Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Istituto Tumori</s1><s2>Milano</s2><s3>ITA</s3><sZ>3 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Istituto Tumori</wicri:noRegion></affiliation></author><author><name sortKey="Simes, John" sort="Simes, John" uniqKey="Simes J" first="John" last="Simes">John Simes</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>NHMRC Clinical Trials Centre</s1><s2>Camperdown</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>NHMRC Clinical Trials Centre</wicri:noRegion></affiliation></author><author><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut Gustaue Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion></affiliation></author><author><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Charite Campus Buch, Robert Roessle Hospital</s1><s2>Berlin</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Issels, Rolf" sort="Issels, Rolf" uniqKey="Issels R" first="Rolf" last="Issels">Rolf Issels</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Klinikum Grosshadern</s1><s2>Munich</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Judson, Ian R" sort="Judson, Ian R" uniqKey="Judson I" first="Ian R." last="Judson">Ian R. Judson</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>8 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van Oosterom, Allan T" sort="Van Oosterom, Allan T" uniqKey="Van Oosterom A" first="Allan T." last="Van Oosterom">Allan T. Van Oosterom</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>University Hospital Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3><sZ>9 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Centre Leon Berard</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0443934</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0443934 INIST</idno><idno type="RBID">Pascal:06-0443934</idno><idno type="wicri:Area/PascalFrancis/Corpus">004164</idno><idno type="wicri:Area/PascalFrancis/Curation">001F31</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003D58</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003D58</idno><idno type="wicri:doubleKey">0959-8049:2006:Van Glabbeke M:predicting:toxicities:for</idno><idno type="wicri:Area/Main/Merge">00A780</idno><idno type="wicri:Area/Main/Curation">009C87</idno><idno type="wicri:Area/Main/Exploration">009C87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib : A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)</title><author><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>EORTC Data Center, Av. E. Mounier, 83, Bte 8</s1><s2>1200, Brussels</s2><s3>BEL</s3><sZ>1 aut.</sZ></inist:fA14><country>Belgique</country><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Erasmus University Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Istituto Tumori</s1><s2>Milano</s2><s3>ITA</s3><sZ>3 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Istituto Tumori</wicri:noRegion></affiliation></author><author><name sortKey="Simes, John" sort="Simes, John" uniqKey="Simes J" first="John" last="Simes">John Simes</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>NHMRC Clinical Trials Centre</s1><s2>Camperdown</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>NHMRC Clinical Trials Centre</wicri:noRegion></affiliation></author><author><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Institut Gustaue Roussy</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion><wicri:noRegion>Institut Gustaue Roussy</wicri:noRegion></affiliation></author><author><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Charite Campus Buch, Robert Roessle Hospital</s1><s2>Berlin</s2><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Issels, Rolf" sort="Issels, Rolf" uniqKey="Issels R" first="Rolf" last="Issels">Rolf Issels</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Klinikum Grosshadern</s1><s2>Munich</s2><s3>DEU</s3><sZ>7 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Judson, Ian R" sort="Judson, Ian R" uniqKey="Judson I" first="Ian R." last="Judson">Ian R. Judson</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>8 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Van Oosterom, Allan T" sort="Van Oosterom, Allan T" uniqKey="Van Oosterom A" first="Allan T." last="Van Oosterom">Allan T. Van Oosterom</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>University Hospital Gasthuisberg</s1><s2>Leuven</s2><s3>BEL</s3><sZ>9 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>University Hospital Gasthuisberg</wicri:noRegion></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Centre Leon Berard</s1><s2>Lyon</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Antineoplastic agent</term><term>Australasia</term><term>Cancer</term><term>Cancerology</term><term>Clinical trial</term><term>Enzyme inhibitor</term><term>Europe</term><term>European Organization for Research and Treatment of Cancer</term><term>Gastrointestinal stromal tumor</term><term>Gut</term><term>Human</term><term>Imatinib</term><term>Italy</term><term>Malignant tumor</term><term>Pharmacology</term><term>Prognosis</term><term>Protein-tyrosine kinase</term><term>Research</term><term>Sarcoma</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Imatinib</term><term>Toxicité</term><term>Homme</term><term>Tumeur maligne</term><term>Stade avancé</term><term>Traitement</term><term>Sarcome</term><term>Protein-tyrosine kinase</term><term>Inhibiteur enzyme</term><term>Europe</term><term>Recherche</term><term>Italie</term><term>Australasie</term><term>Intestin</term><term>Essai clinique</term><term>Pronostic</term><term>Cancérologie</term><term>Pharmacologie</term><term>Anticancéreux</term><term>Tumeur stromale gastrointestinale</term><term>Cancer</term><term>EORTC</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Italie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Recherche</term><term>Pharmacologie</term><term>Cancer</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to identify prognostic factors for toxicity to treatment with imatinib. The study was based on 942 patients with gastrointestinal stromal tumours (GIST) randomised to receive imatinib at different doses. The correlation between toxicities occurring with a Common Toxicity Criteria (CTC) grade 2 or more (non-haematological) or grade 3 or 4 (haematological) and imatinib dose, age, sex, performance status, original disease site, site and size of lesions at trial entry, baseline haematological and biological parameters was investigated. Anaemia was correlated with dose and baseline haemoglobin level, and neutropaenia with baseline neutrophil count and haemoglobin level. The risk of non-haematological toxicities was dose dependent and higher in females (oedema, nausea, diarrhoea), and in patients of advanced age (oedema, rash fatigue), poor performance status (fatigue and nausea), prior chemotherapy (fatigue), tumour of identified gastrointestinal origin (diarrhoea) and small lesions (rash). A multivariate risk calculator that can be used in the clinic for individual patients is proposed.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Auvergne-Rhône-Alpes</li><li>Bavière</li><li>Berlin</li><li>District de Haute-Bavière</li><li>Grand Londres</li><li>Hollande-Méridionale</li><li>Rhône-Alpes</li><li>Région de Bruxelles-Capitale</li></region><settlement><li>Berlin</li><li>Bruxelles</li><li>Londres</li><li>Lyon</li><li>Munich</li><li>Rotterdam</li></settlement></list><tree><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Van Glabbeke, Martine" sort="Van Glabbeke, Martine" uniqKey="Van Glabbeke M" first="Martine" last="Van Glabbeke">Martine Van Glabbeke</name></region><name sortKey="Van Oosterom, Allan T" sort="Van Oosterom, Allan T" uniqKey="Van Oosterom A" first="Allan T." last="Van Oosterom">Allan T. Van Oosterom</name></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Verweij, Jaap" sort="Verweij, Jaap" uniqKey="Verweij J" first="Jaap" last="Verweij">Jaap Verweij</name></region></country><country name="Italie"><noRegion><name sortKey="Casali, Paolo G" sort="Casali, Paolo G" uniqKey="Casali P" first="Paolo G." last="Casali">Paolo G. Casali</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Simes, John" sort="Simes, John" uniqKey="Simes J" first="John" last="Simes">John Simes</name></noRegion></country><country name="France"><noRegion><name sortKey="Le Cesne, Axel" sort="Le Cesne, Axel" uniqKey="Le Cesne A" first="Axel" last="Le Cesne">Axel Le Cesne</name></noRegion><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name></country><country name="Allemagne"><region name="Berlin"><name sortKey="Reichardt, Peter" sort="Reichardt, Peter" uniqKey="Reichardt P" first="Peter" last="Reichardt">Peter Reichardt</name></region><name sortKey="Issels, Rolf" sort="Issels, Rolf" uniqKey="Issels R" first="Rolf" last="Issels">Rolf Issels</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Judson, Ian R" sort="Judson, Ian R" uniqKey="Judson I" first="Ian R." last="Judson">Ian R. Judson</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009C87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009C87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:06-0443934
|texte= Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib : A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)
}}
| This area was generated with Dilib version V0.6.33. |  |